We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-13.26%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.83B
AUM Growth
-$2.02B
Cap. Flow
-$868M
Cap. Flow %
-17.97%
Top 10 Hldgs %
38.68%
Holding
126
New
2
Increased
20
Reduced
30
Closed
20

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$61.8M
2
MASI
Masimo
MASI
+$53.3M
3
CCCC icon
C4 Therapeutics
CCCC
+$49.5M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$28.5M
5
TSVT
2seventy bio
TSVT
+$20.9M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$423M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$112M
3
APLS
Apellis Pharmaceuticals
APLS
+$85.6M
4
ITOS
iTeos Therapeutics
ITOS
+$67.7M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$59.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
26
Stoke Therapeutics
STOK
$2.11B
$76.7M 1.59%
3,644,248
– –
RLMD icon
27
Relmada Therapeutics
RLMD
$527M
$68.6M 1.42%
2,540,074
+353,750
+16% +$7.31M
AXSM icon
28
Axsome Therapeutics
AXSM
$10.9B
$67M 1.39%
1,618,819
– –
RGNX icon
29
Regenxbio
RGNX
$708M
$61.2M 1.27%
1,845,366
– –
ACET icon
30
Adicet Bio
ACET
$74.7M
$59.7M 1.24%
186,843
-2,141
-1% -$492K
BCYC
31
Bicycle Therapeutics
BCYC
$292M
$56M 1.16%
1,276,276
+407,005
+47% +$19M
TXG icon
32
10x Genomics
TXG
$6.61B
$55.9M 1.16%
734,481
– –
IMCR icon
33
Immunocore
IMCR
$1.73B
$55.6M 1.15%
1,859,471
+613,939
+49% +$15.5M
DMTK
34
DELISTED
DermTech, Inc. Common Stock
DMTK
$45.8M 0.95%
3,118,666
– –
GH icon
35
Guardant Health
GH
$22.6B
$45.7M 0.95%
689,887
-123,455
-15% -$8.45M
OM icon
36
Outset Medical
OM
$90.8M
$40.8M 0.85%
59,977
+334
+0.6% +$201K
GHRS icon
37
GH Research
GHRS
$2.08B
$39.7M 0.82%
2,168,957
– –
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
$39.2M 0.81%
5,741,939
– –
QTRX icon
39
Quanterix
QTRX
$190M
$36.4M 0.75%
1,248,517
+562,047
+82% +$17.2M
MGNX icon
40
MacroGenics
MGNX
$257M
$35M 0.72%
3,975,554
– –
TARS icon
41
Tarsus Pharmaceuticals
TARS
$2.84B
$33.9M 0.7%
2,013,601
– –
JNCE
42
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$31.8M 0.66%
4,680,412
+1,817,214
+63% +$13M
IMUX icon
43
Immunic
IMUX
$195M
$30.6M 0.63%
270,551
+99,004
+58% +$11.5M
TNYA icon
44
Tenaya Therapeutics
TNYA
$163M
$29M 0.6%
2,458,750
– –
MIST icon
45
Milestone Pharmaceuticals
MIST
$152M
$27.7M 0.57%
4,315,102
– –
LONA
46
LeonaBio Inc
LONA
$72.1M
$25.7M 0.53%
190,656
– –
CINC
47
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$24.4M 0.5%
+1,389,705
New +$28.5M
OYST
48
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$24M 0.5%
2,058,504
– –
CSTL icon
49
Castle Biosciences
CSTL
$979M
$22.3M 0.46%
496,675
-102,334
-17% -$4.23M
APYX icon
50
Apyx Medical
APYX
$171M
$22.2M 0.46%
3,398,279
– –
1
2
3 4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q1 2022 Portfolio in Review

As of Q1 2022, RTW Investments held 126 positions worth $4.83B, down 29% from $6.85B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

RTW Investments withdrew a net $868M in Q1 2022, closing 20 positions and reducing 30 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $423M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, RTW Investments opened a new position in CinCor Pharma, Inc. Common Stock worth $24.4M.

  • RTW Investments's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 1,389,705 shares worth $24.4M.
  • RTW Investments added most to Protagonist Therapeutics in Q1 2022, an estimated $61.8M increase.
  • RTW Investments's biggest Q1 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $85.6M.
  • RTW Investments fully exited State Street SPDR S&P 500 ETF Trust in Q1 2022, selling an estimated $423M.
  • RTW Investments's ten largest holdings make up 39% of its $4.83B portfolio in Q1 2022.
  • RTW Investments opened 2 new positions and closed 20 in Q1 2022.
  • RTW Investments's portfolio value fell 29% quarter-over-quarter to $4.83B.

Based on RTW Investments's 13F filing for Q1 2022, filed 16 May 2022.